Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ovarian cancer mortality from

Data from the classic Nurses Health Study, followed up in 1994, reflected no difference in all-cause mortality between women who had ever used oral contraceptives and those who had never used them (7). There was also no increase in mortality associated with duration of use and no relation with time since first use or time since last use. Similarly, in the OFPA (Oxford) study, the overall 20-year mortality risk for oral contraceptive users compared with women using diaphragms or IUCDs was 0.9, suggesting no effect (8). Although the number of deaths from each cause was small, the pattern is consistent with the risks found in other studies. Oral contraceptive users had somewhat higher death rates from ischemic heart disease and cervical cancer, but lower rates of ovarian cancer mortality. Breast cancer mortality was similar for oral contraceptive users and non-users. [Pg.214]

Tanioxircn hits seen extensive use in treating primary breast cancers that arc ER dependent, For premenopausal women with metastatic disease, tamoxifen is an alternative and adjuvant with oophorectomy, ovarian irradiation, and mastectomy. Tamoxifen u.se. however, is not problem free. Tamoxifen increases the incidence of endometrial polyps. hyperplasia, and carcinoma and uterine sarcomas. The risk of endometrial cancer resulting from tamoxifen is. however. much lower than the "modest but highly significant reductions in morbidity and mortality of breast cancer." Becau.se of the increased risk of endometrial cancer with tamoxifen therapy, tamoxifen. should be u.sed to prevent breast cancer only in women at high ri.sk. Women without a family history of breast cancer or other risks should not use tamoxifen in this manner. [Pg.782]

Successful screening for ovarian cancer, by definition, is able to decrease mortality and morbidity from the disease. Clinical palpation, transvaginal sonography, and serum CA-125 have been proposed as screening tests for ovarian cancer. Unfortunately,with these tests, routine screening for ovarian cancer is currently not recommended in the general population [3,4,7]. [Pg.234]


See other pages where Ovarian cancer mortality from is mentioned: [Pg.334]    [Pg.799]    [Pg.116]    [Pg.263]    [Pg.457]    [Pg.43]    [Pg.2350]   
See also in sourсe #XX -- [ Pg.2467 ]




SEARCH



Cancer mortality from

Mortality

Ovarian cancer

© 2024 chempedia.info